Antidote funding, valuation and financials

£2.2 M

Antidote Revenue FY, 2017

Antidote Gross profit (FY, 2017)1.3 M

Antidote Gross profit margin (FY, 2017), %58.6%

Antidote Net income (FY, 2017)-4.6 M

Antidote EBITDA (FY, 2017)-4.9 M

Antidote EBIT (FY, 2017)-5 M

Antidote Cash, 31-Dec-20176.1 M

Antidote revenue was £2.15 m in FY, 2017

Embed Graph

Founding Date	2009
Antidote total Funding	$17.9 m
Antidote latest funding size	$13.50 m
Time since last funding	4 years ago
Antidote investors	Amadeus Capital Partners, Smedvig Capital, Octopus Ventures

Antidote's latest funding round in February 2015 was reported to be $13.5 m. In total, Antidote has raised $17.9 m

Embed Graph

GBP	FY, 2015	FY, 2016	FY, 2017
Revenue	2.2m	2.4m	2.2m
Cost of goods sold	912.3k	1.1m	892.3k
Gross profit	1.3m	1.3m	1.3m
Gross profit Margin, %	59%	53%	59%
Operating expense total	3.8m	4.9m	6.2m
EBITDA	(2.5m)	(3.6m)	(4.9m)
EBITDA margin, %	(110%)	(151%)	(229%)
EBIT	(2.5m)	(3.7m)	(5.0m)
EBIT margin, %	(110%)	(152%)	(231%)
Pre tax profit	(2.5m)	(3.7m)	(5.0m)
Income tax expense	218.5k	375.3k	396.4k
Net Income	(2.2m)	(3.3m)	(4.6m)

GBP	FY, 2012	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	284.3k	1.9m	147.5k	1.3m	2.3m	6.1m
Accounts Receivable	73.1k	211.4k	504.2k	647.1k	967.5k	509.6k
Current Assets	357.4k	2.1m	651.8k	2.2m	3.7m	7.2m
PP&E	1.5k	6.7k	14.9k	85.5k	77.0k	66.4k
Total Assets	388.1k	2.1m	666.7k	2.4m	3.9m	7.4m
Accounts Payable	23.9k	61.6k	1.0m	226.3k	77.5k	197.3k
Current Liabilities	23.9k	61.6k	1.0m	442.1k	638.8k	641.4k
Non-Current Liabilities				54.0k	132.5k	90.7k
Total Liabilities	23.9k	61.6k	1.0m	496.0k	771.4k	732.2k
Additional Paid-in Capital	43.0k	45.1k	44.3k	45.0k	45.9k	48.7k
Retained Earnings				(2.2m)	(3.3m)	(4.6m)
Total Equity	364.2k	2.1m	(363.4k)	1.9m	3.1m	6.7m
Financial Leverage	1.1 x	1 x	-1.8 x	1.3 x	1.2 x	1.1 x